Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Plus Therapeutics stock

Own Plus Therapeutics stock in just a few minutes.

Plus Therapeutics, Inc is a biotechnology business based in the US. Plus Therapeutics shares (PSTV) are listed on the NASDAQ and all prices are listed in US Dollars. Plus Therapeutics employs 12 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Plus Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PSTV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Plus Therapeutics share price

Use our graph to track the performance of PSTV stocks over time.

Plus Therapeutics shares at a glance

Information last updated 2021-04-21.
52-week range$1.40 - $4.10
50-day moving average $2.48
200-day moving average $2.46
Wall St. target price$6.75
PE ratio 0.4303
Dividend yield N/A (0%)
Earnings per share (TTM) $-27.98

Buy Plus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Plus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Plus Therapeutics under- or over-valued?

Valuing Plus Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Plus Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Plus Therapeutics's P/E ratio

Plus Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Plus Therapeutics shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Plus Therapeutics financials

Revenue TTM $303,000
Gross profit TTM $-2,397,000
Return on assets TTM -31.14%
Return on equity TTM -393.27%
Profit margin 0%
Book value $0.06
Market capitalisation $18.9 million

TTM: trailing 12 months

Shorting Plus Therapeutics shares

There are currently 379,588 Plus Therapeutics shares held short by investors – that's known as Plus Therapeutics's "short interest". This figure is 125.2% up from 168,536 last month.

There are a few different ways that this level of interest in shorting Plus Therapeutics shares can be evaluated.

Plus Therapeutics's "short interest ratio" (SIR)

Plus Therapeutics's "short interest ratio" (SIR) is the quantity of Plus Therapeutics shares currently shorted divided by the average quantity of Plus Therapeutics shares traded daily (recently around 998915.78947368). Plus Therapeutics's SIR currently stands at 0.38. In other words for every 100,000 Plus Therapeutics shares traded daily on the market, roughly 380 shares are currently held short.

However Plus Therapeutics's short interest can also be evaluated against the total number of Plus Therapeutics shares, or, against the total number of tradable Plus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Plus Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Plus Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0414% of the tradable shares (for every 100,000 tradable Plus Therapeutics shares, roughly 41 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Plus Therapeutics.

Find out more about how you can short Plus Therapeutics stock.

Plus Therapeutics share dividends

We're not expecting Plus Therapeutics to pay a dividend over the next 12 months.

Have Plus Therapeutics's shares ever split?

Plus Therapeutics's shares were split on a 1:50 basis on 5 August 2019. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Plus Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Plus Therapeutics shares which in turn could have impacted Plus Therapeutics's share price.

Plus Therapeutics share price volatility

Over the last 12 months, Plus Therapeutics's shares have ranged in value from as little as $1.4 up to $4.1. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Plus Therapeutics's is 0.3486. This would suggest that Plus Therapeutics's shares are less volatile than average (for this exchange).

Plus Therapeutics overview

Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site